EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data

Heber Rew Bright Bright, Catherine H Smith, Philip Laws, Nick J Reynolds, Duc Binh Phan, Mark Lunt, Richard B Warren, Zenas Z N Yiu

British Journal of Dermatology · 2026-09-15

DOI: 10.1093/bjd/ljag397 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis (TB), meningitis, candidiasis and other fungal infections. However, real-world comparative data including interleukin (IL)-17 and IL-23 inhibitors remain limited. Methods We conducted a nationwide cohort study using data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death or last available follow-up data. Primary outcomes included TB, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years (PY) were calculated and incidence rate ratios (IRRs) were estimated using a doubly robust interval-based Poisson regression model. An entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data. Results A total of 40 930 treatment episodes from 18 635 patients contributing 118 018 PY of follow-up were included in this analysis. During the follow-up, 22 TB cases, 29 meningitis cases and 888 fungal infection cases, including 450 cases of candidiasis, were reported. The overall incidence rates were 0.18 [95% confidence interval (CI) 0.12–0.28] for TB, 0.25 (95% CI 0.16–0.35) for meningitis and 7.53 (95% CI 7.05–8.05) for fungal infections per 1000 PY. Most TB and meningitis cases were associated with tumour necrosis factor-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and TB was largely pulmonary. Thirty-day mortality was seen in < 5 cases in meningitis. IL-17 inhibitors alone exhibited an increased risk of candidiasis compared with all other systemic treatment groups, with IRRs ranging from 2.67 (95% CI 1.33–5.36) vs. apremilast to 4.65 (95% CI 3.46–6.24) vs. the IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the risk of candidiasis. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups. Conclusions In this large cohort study, TB and meningitis were rare and longer-term follow-up is required to further characterize the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks in patients receiving IL-17 inhibitors.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →